Can you take Hexarelin and Triptorelin together?

There is no specific, well-documented interaction rule for combining Hexarelin and Triptorelin in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Hexarelin or Triptorelin?

Hexarelin is currently preclinical only and Triptorelin is research-stage. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

Hexarelin vs Triptorelin

Q: What is the difference between Hexarelin and Triptorelin?

Hexarelin: Hexarelin is a potent synthetic hexapeptide GHRP (Growth Hormone-Releasing Peptide) that stimulates GH release via the ghrelin receptor. It produces among the highest GH pulses of any GHRP, but also elevates cortisol and prolactin — a trade-off that distinguishes it from more selective options like Ipamorelin. Triptorelin: Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Hexarelin

Preclinical only

Hexarelin is a potent synthetic hexapeptide GHRP (Growth Hormone-Releasing Peptide) that stimulates GH release via the ghrelin receptor. It produces among the highest GH pulses of any GHRP, but also elevates cortisol and prolactin — a trade-off that distinguishes it from more selective options like Ipamorelin.

Full profile

Triptorelin

Research-stage

Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.

Full profile

	Hexarelin	Triptorelin
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	Examorelin, EP 23905, MF-6003	GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH
Evidence	Preclinical only	Research-stage
Dosing range	50mcg–200mcg mcg, 1–3x daily (cycling recommended to prevent desensitization)	50mcg–200mcg mcg, Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical)
Administration	Subcutaneous injection, Intramuscular injection	Intramuscular injection, Subcutaneous injection
Key side effects	Cortisol elevation, Prolactin elevation, Water retention, Increased appetite	Initial testosterone surge followed by suppression (with repeated dosing), Hot flashes, Decreased libido, Bone density loss (long-term repeated dosing)
Cited sources	1 reference	2 references

Key differences

Evidence level differs: Hexarelin is preclinical only, while Triptorelin is research-stage.
Administration: Hexarelin — Subcutaneous injection, Intramuscular injection; Triptorelin — Intramuscular injection, Subcutaneous injection.
Frequency: Hexarelin is typically 1–3x daily (cycling recommended to prevent desensitization); Triptorelin is Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical).
Research depth: this profile cites 1 source for Hexarelin vs 2 for Triptorelin.

How each works

Hexarelin

Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.

Triptorelin

Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.

Read the full Hexarelin profile Read the full Triptorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.